Luminex inks licensing deal with ViroNovative for intellectual property

Tweet   

Luminex Corporation (Nasdaq:LMNX) announced today it had signed a licensing agreement that gives it the rights to use ViroNovative BV’s human metapneumovirus intellectual property. Luminex is an Austin, Texas-based manufacturer and developer of biological testing technologies. According to the agreement’s terms, the rights to ViroNovative’s human metapneumovirus would extend to Luminex’s distributors and customers worldwide.

“We are pleased to announce this license agreement in place with ViroNovative for human metapneumovirus,” said Jeremy Bridge-Cook, vice president of Luminex Molecular Diagnostics, in a statement. “This virus is of increasing concern to health care providers worldwide. Having this license as part of our xTAG RVP assay is important to us as it allows our customers to use this cutting-edge test without the need to individually secure rights to this intellectual property.”

Luminex’s xTAG RVP detects and identifies 12 viruses that are responsible for more than 85% of respiratory viral infections, the company said.

In today’s trading, shares of Luminex are mostly flat, down about $0.02 to $20.40 at 1:37 p.m. ET. During the past year, the stock has ranged from $11.65 to $23.09.

For detailed price information and recent news stories on Luminex Corporation, click LMNX.